Panel, Fireside Chat
Dr. Susan David, Alex Gorsky, and Dr. Mark McClellan
- Emotional agility is projected to enable individuals and businesses to adapt to current conditions, with leaders encouraged to embrace uncertainty to redefine their organizational visions.
- Organizations are expected to pause and reexamine systemic bureaucratic processes to determine more effective and growth-oriented operational methods.
- Johnson & Johnson employees are anticipated to continue operations in critical facilities to ensure medicine distribution and maintain clinical trial progress while prioritizing safety, job stability, and family support.
- The company has committed 190% of its resources to pivoting efforts toward vaccine development, with a candidate scheduled for human testing in the latter weeks of July.
- Vaccine production aims to scale to hundreds of millions of doses quickly, representing a Herculean acceleration of the typical five-to-seven-year development cycle into a five-to-six-month timeframe.
- The vaccine candidate relies on data from animal models using a carrier virus platform, requiring further testing to translate results to humans and will likely function as part of a broader strategy involving therapeutics and protocols rather than as a standalone solution.
- Johnson & Johnson plans to distribute the vaccine on a not-for-profit basis to both developed and developing nations while dozens of other candidates utilizing RNA, DNA, and mRNA vector platforms continue development.
- Healthcare systems are expected to possess excess capacity following early closures, though case rates are predicted to rise in areas with previously low incidence, potentially increasing hospital occupancy if reopening occurs without caution.
- Testing access is projected to improve nationally despite uneven business resources, with states establishing contact tracing programs and issuing specific reopening guidelines for businesses.
- The broader healthcare landscape is expected to shift toward national, economic, and social security models, requiring decades of investment to strengthen public health infrastructure and foster collaboration between FDA, government, and industry.
- Future healthcare delivery is anticipated to see increased telemedicine usage, alongside reforms in Medicare and private insurance payment structures to prioritize community-based care, prevention, and the mitigation of disparities through partnerships between policymakers, insurers, and small businesses.